The DOI matches its Crossref record; 57 of the 57 references it cites were found in a registry or an index.
New oral anticoagulants: their advantages and disadvantages compared with vitamin K antagonists in the prevention and treatment of patients with thromboembolic events
Open accessAbstract
Despite the discovery and application of many parenteral (unfractionated and low-molecular-weight heparins) and oral anticoagulant vitamin K antagonist (VKA) drugs, the prevention and treatment of venous and arterial thrombotic phenomena remain major medical challenges. Furthermore, VKAs are the only oral anticoagulants used during the past 60 years. The main objective of this study is to present recent data on non-vitamin K antagonist oral anticoagulants (NOACs) and to analyze their advantages and disadvantages compared with those of VKAs based on a large number of recent studies. NOACs are novel direct-acting medications that are selective for one specific coagulation factor, either thrombin (IIa) or activated factor X (Xa). Several NOACs, such as dabigatran (a direct inhibitor of FIIa) and rivaroxaban, apixaban and edoxaban (direct inhibitors of factor Xa), have been used for at least 5 years but possibly 10 years. Unlike traditional VKAs, which prevent the coagulation process by suppressing the synthesis of vitamin K-dependent factors, NOACs directly inhibit key proteases (factors IIa and Xa). The important indications of these drugs are the prevention and treatment of deep vein thrombosis and pulmonary embolisms, and the prevention of atherothrombotic events in the heart and brain of patients with acute coronary syndrome and atrial fibrillation. They are not fixed, and dose-various strengths are available. Most studies have reported that more advantages than disadvantages for NOACs when compared with VKAs, with the most important advantages of NOACs including safety issues (ie, a lower incidence of major bleeding), convenience of use, minor drug and food interactions, a wide therapeutic window, and no need for laboratory monitoring. Nonetheless, there are some conditions for which VKAs remain the drug of choice. Based on the available data, we can conclude that NOACs have greater advantages and fewer disadvantages compared with VKAs. New studies are required to further assess the efficacy of NOACs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
Oral Rivaroxaban for Symptomatic Venous Thromboembolism
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1007903 · Cited by 3,237
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Schulman, S., Kearon, C., Kakkar, A. K., Mismetti, P., Schellong, S., Eriksson, H., Baanstra, D., Schnee, J., & Goldhaber, S. Z. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0906598 · Cited by 2,583
Büller (2012) · doi:10.1056/nejmoa1113572 · Cited by 2,353
Rivaroxaban in Patients with a Recent Acute Coronary Syndrome
Mega, J. L., Braunwald, E., Wiviott, S. D., Bassand, J.-P., Bhatt, D. L., Bode, C., Burton, P., Cohen, M., Cook-Bruns, N., Fox, K. A. A., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1112277 · Cited by 1,897
Edoxaban versus Warfarin for the Treatment of Symptomatic Venous Thromboembolism
The Hokusai-VTE Investigators (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1306638 · Cited by 1,869
Oral Anticoagulants: Mechanism of Action, Clinical Effectiveness, and Optimal Therapeutic Range
Hirsh, J., Dalen, J. E., Anderson, D. R., Poller, L., Bussey, H., Ansell, J., & Deykin, D. (2001) · Chest · doi:10.1378/chest.119.1_suppl.8s · Cited by 1,804
Dabigatran versus warfarin in patients with mechanical heart valves
Eikelboom, J. W., Connolly, S. J., Brueckmann, M., Granger, C. B., Kappetein, A. P., Mack, M. J., Blatchford, J., Devenny, K., Friedman, J., Guiver, K., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1300615 · Cited by 1,506
Stangier, J., Haertter, S., Liesenfeld, K.-H., Wienen, W., Feuring, M., Clemens, A., & Ryn, J. V. (2010) · Thrombosis and Haemostasis · doi:10.1160/th09-11-0758 · Cited by 1,382
Treatment of Acute Venous Thromboembolism With Dabigatran or Warfarin and Pooled Analysis
Schulman, S., Kakkar, A. K., Goldhaber, S. Z., Schellong, S., Eriksson, H., Mismetti, P., Christiansen, A. V., Friedman, J., Le Maulf, F., Peter, N., et al. (2014) · Circulation · doi:10.1161/circulationaha.113.004450 · Cited by 923
Stangier, J., Rathgen, K., Stähle, H., Gansser, D., & Roth, W. (2007) · British Journal of Clinical Pharmacology · doi:10.1111/j.1365-2125.2007.02899.x · Cited by 887
Heidbuchel, H., Verhamme, P., Alings, M., Antz, M., Hacke, W., Oldgren, J., Sinnaeve, P., Camm, A. J., & Kirchhof, P. (2013) · Europace · doi:10.1093/europace/eut083 · Cited by 792
Lu, G., DeGuzman, F. R., Hollenbach, S. J., Karbarz, M. J., Abe, K., Lee, G., Luan, P., Hutchaleelaha, A., Inagaki, M., Conley, P. B., et al. (2013) · Nature Medicine · doi:10.1038/nm.3102 · Cited by 701
The Metabolism and Disposition of the Oral Direct Thrombin Inhibitor, Dabigatran, in Humans
Blech, S., Ebner, T., Ludwig-Schwellinger, E., Stangier, J., & Roth, W. (2008) · Drug Metabolism and Disposition · doi:10.1124/dmd.107.019083 · Cited by 689
KUBITZA, D., BECKA, M., VOITH, B., ZUEHLSDORF, M., & WENSING, G. (2005) · Clinical Pharmacology & Therapeutics · doi:10.1016/j.clpt.2005.06.011 · Cited by 649
Graham, D. J., Reichman, M. E., Wernecke, M., Zhang, R., Southworth, M. R., Levenson, M., Sheu, T.-C., Mott, K., Goulding, M. R., Houstoun, M., et al. (2015) · Circulation · doi:10.1161/circulationaha.114.012061 · Cited by 644
Kubitza, D., Becka, M., Wensing, G., Voith, B., & Zuehlsdorf, M. (2005) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-005-0043-5 · Cited by 640
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients
Cohen, A. T., Spiro, T. E., Büller, H. R., Haskell, L., Hu, D., Hull, R., Mebazaa, A., Merli, G., Schellong, S., Spyropoulos, A. C., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1111096 · Cited by 607
Hohnloser, S. H., Oldgren, J., Yang, S., Wallentin, L., Ezekowitz, M., Reilly, P., Eikelboom, J., Brueckmann, M., Yusuf, S., & Connolly, S. J. (2012) · Circulation · doi:10.1161/circulationaha.111.055970 · Cited by 348
Connolly, S., Patel, I., Salazar, D., Rohatagi, S., Mendell, J., Kastrissios, H., Jin, J., Kunitada, S., & Weitz, J. (2010) · Thrombosis and Haemostasis · doi:10.1160/th10-01-0066 · Cited by 341
Eriksson, B. I., Borris, L. C., Dahl, O. E., Haas, S., Huisman, M. V., Kakkar, A. K., Muehlhofer, E., Dierig, C., Misselwitz, F., & Kälebo, P. (2006) · Circulation · doi:10.1161/circulationaha.106.642074 · Cited by 335
Kubitza, D., Becka, M., Zuehlsdorf, M., & Mueck, W. (2007) · The Journal of Clinical Pharmacology · doi:10.1177/0091270006296058 · Cited by 334
Crowther, M. A., & Warkentin, T. E. (2008) · Blood · doi:10.1182/blood-2007-10-120543 · Cited by 314
TURPIE, A. G. G., FISHER, W. D., BAUER, K. A., KWONG, L. M., IRWIN, M. W., KÄLEBO, P., MISSELWITZ, F., & GENT, M. (2005) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2005.01602.x · Cited by 302
FURUGOHRI, T., ISOBE, K., HONDA, Y., KAMISATO‐MATSUMOTO, C., SUGIYAMA, N., NAGAHARA, T., MORISHIMA, Y., & SHIBANO, T. (2008) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2008.03064.x · Cited by 301
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran
Stangier, J., & Feuring, M. (2012) · Blood Coagulation & Fibrinolysis · doi:10.1097/mbc.0b013e32834f1b0c · Cited by 265
Wang, L., Zhang, D., Raghavan, N., Yao, M., Ma, L., Frost, C. A., Maxwell, B. D., Chen, S.-Y., He, K., Goosen, T. C., et al. (2010) · Drug Metabolism and Disposition · doi:10.1124/dmd.109.029694 · Cited by 253
Eikelboom, J. W., & Weitz, J. I. (2010) · Circulation · doi:10.1161/circulationaha.109.853119 · Cited by 245
Contant, G., Spiro, T., Perzborn, E., Guinet, C., Gourmelin, Y., Flem, L., Rohde, G., Martinoli, J., Samama, M., & Laboratories, F. T. R. A.-F. X. C. A. F. T. (2012) · Thrombosis and Haemostasis · doi:10.1160/th11-06-0391 · Cited by 232
Pros and cons of new oral anticoagulants
Bauer, K. A. (2013) · Hematology · doi:10.1182/asheducation-2013.1.464 · Cited by 226
Turpie, A. G. G. (2007) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.107.139402 · Cited by 224
In Vitro and In Vivo P-Glycoprotein Transport Characteristics of Rivaroxaban
Gnoth, M. J., Buetehorn, U., Muenster, U., Schwarz, T., & Sandmann, S. (2011) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.111.180240 · Cited by 216
Gómez-Outes, A., Terleira-Fernández, A. I., Calvo-Rojas, G., Suárez-Gea, M. L., & Vargas-Castrillón, E. (2013) · Thrombosis · doi:10.1155/2013/640723 · Cited by 185
Mueck, W., Schwers, S., & Stampfuss, J. (2013) · Thrombosis Journal · doi:10.1186/1477-9560-11-10 · Cited by 165
Frost, C. E., Song, Y. J., Barrett, Y. C., Wang, J. J. J., Pursley, J. M., Boyd, R. A., & LaCreta, F. P. (2014) · Clinical Pharmacology Advances and Applications · doi:10.2147/cpaa.s61131 · Cited by 122
Kubitza, D., Becka, M., Roth, A., & Mueck, W. (2013) · The Journal of Clinical Pharmacology · doi:10.1002/jcph.5 · Cited by 116
Use of Anticoagulation in Elderly Patients with Atrial Fibrillation Who Are at Risk for Falls
Garwood, C. L., & Corbett, T. L. (2008) · Annals of Pharmacotherapy · doi:10.1345/aph.1k498 · Cited by 103
New Oral Anticoagulants in Practice: Pharmacological and Practical Considerations
Wang, Y., & Bajorek, B. V. (2014) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-013-0061-0 · Cited by 95
Rivaroxaban: An oral direct inhibitor of factor Xa
Gulseth, M. P., Michaud, J. B., & Nutescu, E. A. (2008) · American Journal of Health-System Pharmacy · doi:10.2146/ajhp070624 · Cited by 93
Artang, R., Rome, E., Nielsen, J. D., & Vidaillet, H. J., Jr. (2013) · The American Journal of Cardiology · doi:10.1016/j.amjcard.2013.08.027 · Cited by 91
Dabigatran versus Warfarin in the Treatment of Acute Venous Thromboembolism
Moneta, G. L. (2010) · Yearbook of Vascular Surgery · doi:10.1016/s0749-4041(09)79275-9 · Cited by 87
Yin, O. Q. P., Kimura, T., & Miller, R. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1736-4 · Cited by 71
Apixaban, an oral, direct inhibitor of activated Factor Xa.
Shantsila, E., & Lip, G. Y. H. (2008) · PubMed · Cited by 51
Douxfils, J., Tamigniau, A., Châtelain, B., Goffinet, C., Dogné, J.-M., & Mullier, F. (2014) · Thrombosis Journal · doi:10.1186/1477-9560-12-24 · Cited by 47
New oral anticoagulants: will they replace warfarin?
Little, J. W. (2012) · Oral Surgery Oral Medicine Oral Pathology and Oral Radiology · doi:10.1016/j.oooo.2011.10.006 · Cited by 43
Hirschl, M., & Kundi, M. (2014) · VASA · doi:10.1024/0301-1526/a000373 · Cited by 38
Rognoni, C., Marchetti, M., Quaglini, S., & Liberato, N. L. (2014) · Journal of Thrombosis and Thrombolysis · doi:10.1007/s11239-014-1104-3 · Cited by 36
Novel Oral Anticoagulants in Cardiovascular Disease
Gallego, P., Roldán, V., & Lip, G. Y. H. (2013) · Journal of Cardiovascular Pharmacology and Therapeutics · doi:10.1177/1074248413501392 · Cited by 29
A case report describing a suspected rivaroxaban hypersensitivity reaction in a surgical patient
Yates, J., Choudhry, M., & Keys, G. W. (2012) · Journal of Clinical Pharmacy and Therapeutics · doi:10.1111/jcpt.12013 · Cited by 28
Novel oral Anticoagulants in Non-Valvular Atrial Fibrillation
da Silva, R. M. F. L. (2014) · Cardiovascular & Hematological Agents in Medicinal Chemistry · doi:10.2174/187152571201141201091848 · Cited by 28
The promise of novel direct oral anticoagulants
Hoffman, R., & Brenner, B. (2012) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2012.06.004 · Cited by 25
Direct oral anticoagulants: integration into clinical practice
Cowell, R. P. W. (2014) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2013-132474 · Cited by 23
Non-vitamin K Antagonist Oral Anticoagulants (NOACs): a View from the Laboratory
Blann, A. D. (2014) · British Journal of Biomedical Science · doi:10.1080/09674845.2014.11669981 · Cited by 14
Practical management of new oral anticoagulants after total hip or total knee arthroplasty
Klauser, W., & Dütsch, M. (2013) · MUSCULOSKELETAL SURGERY · doi:10.1007/s12306-013-0306-8 · Cited by 14
(2013) · Cardiovascular Medicine · doi:10.4414/cvm.2013.00146 · Cited by 10
Cited by
U.S. FDA Approved Drugs from 2015–June 2020: A Perspective
Bhutani, P., Joshi, G., Raja, N., Bachhav, N., Rajanna, P. K., Bhutani, H., Paul, A. T., & Kumar, R. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01786 · Cited by 815
Metadata
- Authors
- Mekaj, A., Mekaj, Y., Duci, S., & Miftari, E.
- Venue
- Therapeutics and Clinical Risk Management
- Publisher
- Informa UK Limited
- Published
- 2015-06
- Volume
- 11
- Pages
- 967
- ISSN
- 1176-6336 (ISSN-L)
- 1178-203X
- OpenAlex
- W1479868810
- Cited by
- 407
- References
- 57
- FWCI
- 24.91
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.